Skip to content

A cross-sectional multi-omics study of neuropathic pain after spinal cord injury

A cross-sectional multi-omics study of neuropathic pain after spinal cord injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099100
Enrollment
Unknown
Registered
2025-03-18
Start date
2025-03-20
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal cord injury

Interventions

NP group (neuropathic pain group):nonintervention
Non-NP group (non-neuropathic pain group):nonintervention

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for SCI in the international standard of neurological classification; 2. Confirmed by imaging examination of definite spinal cord injury; 3. Spinal cord injury caused by traumatic causes; 4. ASIA is graded as A; Spinal cord injury for 3 months or more; 5. After spinal cord injury, he has only undergone spinal cord decompression surgery related to unopened dural sac; 6. Taking anti-inflammatory and analgesic drugs, central analgesic drugs, antidepressant drugs and using intrathecal analgesic pumps and other means for analgesia or not using the above treatment measures for analgesia; 7. Age 18-70 years old; 8. Gender is male and female with no significant difference in estrogen levels; 9. The injured segment is the thoracic segment; 10. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pain caused by other spinal diseases, diabetic peripheral neuropathy, herpes zoster or other traumatic diseases; 2. Accompanied by diseases of heart, lungs, brain and other important organs; 3. Chronic digestive tract and digestive gland diseases, such as hepatobiliary and pancreatic diseases, irritable bowel syndrome, etc., as well as taking unconventionally prescribed digestive system drugs; 4. Patients with metabolic diseases, such as diabetes, obesity patients with a BMI of > 30, etc., as well as taking endocrinology-related drugs; 5. Suffering from blood diseases, such as leukemia, etc., and taking drugs for blood diseases; 6. Suffering from rheumatic immune system diseases, such as multiple sclerosis, etc., as well as taking anti-rheumatic immune drugs; 7. Suffering from mental illness and neurological diseases, such as autism, depression and Parkinson's disease; 8. Suffering from allergic diseases, such as asthma, urticaria, etc., as well as taking anti-allergic drugs; 9. Suffering from infectious diseases, such as intestinal infection, HIV, etc., and taking antibiotic treatment; 10. Tumors are currently suffering from and receiving any form of anti-tumor therapy; 11. Unable to cooperate with the completion of fecal sample collection; 12. Abnormal bowel habits in the past week; 13. Changes in eating habits in the past week; 14. Have special dietary habits, such as vegetarians, Muslims, etc.; 15. The clinical data are incomplete.

Design outcomes

Primary

MeasureTime frame
Intestinal microbiota abundance;Concentration and composition of short-chain fatty acids (SCFAs).;Correlation of clinical presentation;

Countries

China

Contacts

Public ContactChen Zixian

Zhongshan Hospital, Fudan University

chen.zixian@zs-hospital.sh.cn+86 139 1823 8859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026